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Galantamine improves cognition, hippocampal inflammation, and synaptic 
plasticity impairments induced by lipopolysaccharide in mice 
Abstract 
Background: Neuroinflammation plays an important role in the onset and progression of 
neurodegenerative diseases such as Alzheimer's disease. Lipopolysaccharide (LPS, endotoxin) levels are 
higher in the brains of Alzheimer's disease patients and are associated with neuroinflammation and 
cognitive decline, while neural cholinergic signaling controls inflammation. This study aimed to examine 
the efficacy of galantamine, a clinically approved cholinergic agent, in alleviating LPS-induced 
neuroinflammation and cognitive decline as well as the associated mechanism. 
Methods: Mice were treated with galantamine (4 mg/kg, intraperitoneal injection) for 14 days prior to LPS 
exposure (intracerebroventricular injection). Cognitive tests were performed, including the Morris water 
maze and step-through tests. mRNA expression of the microglial marker (CD11b), astrocytic marker 
(GFAP), and pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) were examined in the hippocampus by 
quantitative RT-PCR. The inflammatory signaling molecule, nuclear factor-kappa B (NF-ΚB p65), and 
synapse-associated proteins (synaptophysin, SYN, and postsynaptic density protein 95, PSD-95) were 
examined in the hippocampus by western blotting. Furthermore, NF-ΚB p65 levels in microglial cells and 
hippocampal neurons were examined in response to LPS and galantamine. 
Results: Galantamine treatment prevented LPS-induced deficits in spatial learning and memory as well as 
memory acquisition of the passive avoidance response. Galantamine decreased the expression of 
microglia and astrocyte markers (CD11b and GFAP), pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α), 
and NF-ΚB p65 in the hippocampus of LPS-exposed mice. Furthermore, galantamine ameliorated LPS-
induced loss of synapse-associated proteins (SYN and PSD-95) in the hippocampus. In the in vitro study, 
LPS increased NF-ΚB p65 levels in microglia (BV-2 cells); the supernatant of LPS-stimulated microglia 
(Mi-sup), but not LPS, decreased the viability of hippocampal neuronal cells (HT-22 cells) and increased 
NF-ΚB p65 levels as well as expression of pro-inflammatory cytokines (IL-1β, IL-6) in HT-22 cells. 
Importantly, galantamine reduced the inflammatory response not only in the BV-2 microglia cell line, but 
also in the HT-22 hippocampal neuronal cell line. 
Conclusions: These findings indicate that galantamine could be a promising treatment to improve 
endotoxin-induced cognitive decline and neuroinflammation in neurodegenerative diseases. 
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Abstract
Background: Neuroinflammation plays an important role in the onset and progression of neurodegenerative
diseases such as Alzheimer’s disease. Lipopolysaccharide (LPS, endotoxin) levels are higher in the brains of
Alzheimer’s disease patients and are associated with neuroinflammation and cognitive decline, while neural
cholinergic signaling controls inflammation. This study aimed to examine the efficacy of galantamine, a clinically
approved cholinergic agent, in alleviating LPS-induced neuroinflammation and cognitive decline as well as the
associated mechanism.
Methods: Mice were treated with galantamine (4 mg/kg, intraperitoneal injection) for 14 days prior to LPS
exposure (intracerebroventricular injection). Cognitive tests were performed, including the Morris water maze and
step-through tests. mRNA expression of the microglial marker (CD11b), astrocytic marker (GFAP), and pro-
inflammatory cytokines (IL-1β, IL-6, and TNF-α) were examined in the hippocampus by quantitative RT-PCR. The
inflammatory signaling molecule, nuclear factor-kappa B (NF-κB p65), and synapse-associated proteins
(synaptophysin, SYN, and postsynaptic density protein 95, PSD-95) were examined in the hippocampus by western
blotting. Furthermore, NF-κB p65 levels in microglial cells and hippocampal neurons were examined in response to
LPS and galantamine.
Results: Galantamine treatment prevented LPS-induced deficits in spatial learning and memory as well as memory
acquisition of the passive avoidance response. Galantamine decreased the expression of microglia and astrocyte
markers (CD11b and GFAP), pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α), and NF-κB p65 in the hippocampus
of LPS-exposed mice. Furthermore, galantamine ameliorated LPS-induced loss of synapse-associated proteins (SYN
and PSD-95) in the hippocampus. In the in vitro study, LPS increased NF-κB p65 levels in microglia (BV-2 cells); the
supernatant of LPS-stimulated microglia (Mi-sup), but not LPS, decreased the viability of hippocampal neuronal cells
(HT-22 cells) and increased NF-κB p65 levels as well as expression of pro-inflammatory cytokines (IL-1β, IL-6) in
HT-22 cells. Importantly, galantamine reduced the inflammatory response not only in the BV-2 microglia cell line,
but also in the HT-22 hippocampal neuronal cell line.
Conclusions: These findings indicate that galantamine could be a promising treatment to improve endotoxin-induced
cognitive decline and neuroinflammation in neurodegenerative diseases.
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Background
Neuroinflammation has been considered as a critical
driver of cognitive deficits associated with several
neurodegenerative diseases, such as Alzheimer’s dis-
ease, diabetic encephalopathy, and amyotrophic lat-
eral sclerosis [1–3]. Hippocampal inflammation has
been reported to contribute to postoperative cognitive de-
cline and Alzheimer’s disease [4, 5]. Lipopolysaccharide
(LPS, endotoxin), a cell wall component of gram-negative
bacteria, has been shown to induce hippocampal neuroin-
flammation and cognitive impairment and is widely used
in preclinical models to model the postoperative cognitive
dysfunction (POCD) [6–9]. The levels of LPS and its
related gram-negative Escherichia coli bacteria were
reported to be higher in the brains of subjects with
Alzheimer’s disease [10]. However, the mechanisms
underlying the role of LPS in deleterious neuroinflamma-
tion in cognitive decline are poorly understood.
Neuroglial cells are essential for the maintenance of
brain homeostasis; however, overactivated neuroglial
cells, such as microglia and astrocytes, contribute to
neuroinflammation and neurodegenerative disorders
[11]. Enhanced expression of CD11b, a β-integrin
marker of microglia, represents microglial activation
during neurodegenerative inflammation [12]. Activation
of the nuclear factor-kappa B (NF-κB) in microglia pro-
motes gene expression of pro-inflammatory cytokines,
such as interleukin 1β and 6 (IL-1β, IL-6) and tumor ne-
crosis factor-α (TNF-α), which contribute to neurode-
generative disorders [13, 14]. Glial fibrillary acidic
protein (GFAP) is a marker for astrogliosis [15].
Recently, it has been reported that LPS activates pro-
inflammatory microglia, while astrocytes existing alone
in culture cannot respond to LPS, as rodent astrocytes
lack TLR4 and MYD88 downstream signaling compo-
nents required for LPS activation [11].
Cognitive impairment is associated with synaptic
abnormalities in the hippocampus [16]. Pre-synaptic
and post-synaptic proteins such as synaptophysin
(SYN) and postsynaptic density protein (PSD-95), re-
spectively, play important roles in synaptic plasticity
and cognitive function [17]. SYN protein levels are
lower in oldest-aged individuals with dementia [18].
PSD-95 levels are decreased in brains of patients with
Alzheimer’s disease compared to controls [19]. It has
been shown that there is a direct interaction between
neuroinflammation and SYN as well as PSD-95 in
newborn neurons [20, 21]. Co-activation of proinflamma-
tory cytokines and cytotoxic products in neuro-
inflammation processes are destructive to neurons by
altering synaptic proteins [21]. Therefore, the
neuroinflammatory response may induce the loss of
synaptic proteins and cognitive deficits in neurodegen-
erative illness.
Galantamine is an alkaloid obtained from the bulbs and
flowers of the Caucasian snowdrop (Vornonov’s snow-
drop) and Lycoris radiate (Red Spider Lily)-related species
[22]. Pharmacokinetic studies demonstrate that galanta-
mine can quickly cross the blood-brain barrier and remain
in brain regions, such as the hippocampus, for an ex-
tended time (biological half-life is 5–7 h) [23, 24].
Galantamine, a centrally acting acetyl-cholinesterase
(AChE) inhibitor, is used safely in elderly Alzheimer’s pa-
tients to improve cognitive function [25]. Galantamine in-
creases the release of Ach in the hippocampus, which is
essential for learning and memory [26, 27]. Recent studies
have demonstrated that galantamine has significant anti-
inflammatory effects in vitro and in vivo. For example,
galantamine and nicotine have a synergistic effect on in-
hibition of TNF-α release and cellular activation in a cul-
tured microglia model of HIV-associated dementia [28].
In mice, galantamine decreases serum TNF-α and IL-6
concentrations and enhances the survival of mice follow-
ing an intraperitoneal injection of lethal and inflamma-
tory doses of LPS [29]. However, the ability of
galantamine to prevent LPS-induced cognitive decline
is yet to be reported and the mechanisms underlying
its cognitive enhancing and anti-neuroinflammation
properties remained to be clarified. In the present
study, we examined if galantamine could improve
cognitive behavior and neuronal morphology in a
neuroinflammation mouse model developed using in-
tracerebroventricular (ICV) administration of LPS. To
further investigate the underlying mechanisms, the
hippocampal synaptic proteins (SYN and PSD-95),
neuroglial cell markers (CD11b and GFAP), the pro-
inflammatory transcription factor, NF-κB p65, and cy-
tokines (IL-1β, TNF-α and IL-6) were also examined
in the hippocampus. Moreover, to investigate the pre-
cise cell and molecular mechanism of LPS-induced
neuroinflammation and the specific anti-inflammatory
target of galantamine, the NF-κB p65 levels in micro-
glia cells and hippocampal neurons were examined in
response to LPS and galantamine.
Methods
Animals
Male Kunming mice (6 weeks old weighing 18–22 g) were
used in the present study. The mice were obtained from
the Experimental Animal Center of Xuzhou Medical
University (Xuzhou, China, SCXK(Su)2015-0009). The
mice were housed with ad libitum access to food and
water under temperature- and humidity-controlled condi-
tions with a 12-h light/dark cycle. All procedures were ap-
proved by the Animal Ethics Committee, Xuzhou Medical
University, China, and complied with the National
Institutes of Health Guidelines for the Care and Use of
Laboratory Animals.
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Experimental protocol
The mice were randomized into four groups (n = 13 per
group): (1) the control group—vehicle treatment and ICV
injection of saline; (2) the LPS group—vehicle treatment
and ICV injection of LPS; (3) the galantamine treatment
group (LPS + galantamine)—galantamine followed by LPS
ICV injection; (4) the galantamine control group (galanta-
mine)—galantamine followed by saline ICV injection.
Mice were injected with LPS (8 μg/μl in 3 μl, ICV) or sa-
line into the lateral ventricle (AP − 0.46, ML − 1.0, and
DV − 1.8) as previously described [30]. Mice were con-
tinuously treated with galantamine (4 mg/kg, ip injection)
or vehicle treatment for 14 days starting 1 day before the
LPS injection. This dosage of galantamine is in accordance
with previous studies showing that it inhibits peripheral
inflammation in rodents [31, 32]. Galantamine hydrobro-
mide was purchased from Shanghai Xudong Haipu
Pharmaceutical Co., Ltd. (Shanghai, China). LPS
(Escherichia coli, serotype 0127: B8) was purchased from
Sigma (St. Louis, MO, USA). Similar to previous studies
[8, 33], behavioral tests were assessed 5 days after the LPS
injection (10 mice per group). Within 1 day after the final
test, mice were sacrificed and the hippocampus were col-
lected: the left hippocampus was used to measure CD11b,
GFAP, IL-1β, IL-6, and TNF-α by RT-PCR (n = 5 per
group); the right hippocampus was used to measure NF-
κB p65, SYN, and PSD-95 by western blot (n = 5 per
group); neuronal morphometry by Golgi staining was also
performed on the remaining three of each group that did
not undergo behavioral testing.
Behavioral tests
Morris water maze test
As previously described [34], the Morris water maze
(MWM) test included four consecutive daily training tri-
als and a probe trial on the fifth day. The test was per-
formed in a circular pool (120 cm in diameter and
60 cm in height) filled with water. The pool was divided
into four quadrants with an escape platform (10 cm in
diameter) hidden in water in the center of one quadrant.
During training trials, the time that the mice spent to
reach the hidden platform was recorded as escape la-
tency. On the probe trial, the platform was removed.
The time taken to cross the former platform location
was recorded to indicate the degree of memory
consolidation.
Step-through test
The step-through test was performed to examine memory
acquisition as previously described [35, 36]. Briefly, the
test included a training trial on the first day and retention
trial on the second day. The apparatus consisted of a com-
partment with two chambers (a light chamber equipped
with an illuminator and a dark chamber) and an
interconnecting semicircular door. During the training
trial, the mice were placed in the light chamber for 3 min.
After the door opened, the mice moved to the dark cham-
ber and received a footshock for 1 s. During the retention
trial, the number of mistakes and the time that the mice
took before initially entering the dark chamber (the step-
through latency) were recorded for 5 min.
Reverse transcriptase-PCR (RT-PCR)
After total RNA was extracted using TRI reagent (Sigma-
Aldrich, MO, USA), cDNA was synthesized by a High-
Capacity RNA-to-cDNA kit (Sigma-Aldrich, MO, USA).
The primers for CD11b, GFAP, IL-1β, IL-6, TNF-α, and
the housekeeping gene β-actin (Sangon Biotech Co. Ltd.,
Shanghai, China) are listed in Table 1. Agarose gel electro-
phoresis was used to separate amplified products followed
by a UV trans-illuminator and photography for
visualization. Duplicate reaction was performed to verify
reproducibility. The values obtained for the target gene
expression were normalized to β-actin and quantified rela-
tive to the expression in control samples. The products
were analyzed by densitometry using the Quantity One 1-
D analysis software (BioRad, Hercules, CA, USA).
Quantitative real-time PCR (qPCR)
Total RNA was isolated from hippocampal neuronal
cells (HT-22 cells), using the TRIzol® reagent (Invitrogen
Co., Carlsbad, CA, USA) according to the manufac-
turer’s instructions. The concentration and purity of
total RNA were determined using NanoDrop 1000
(Thermo Scientific). The Rever TraAce qPCR RT kit
(TOYOBO) was used for the reverse transcription of
total RNA to cDNA. In real-time experiments, cDNA
was analyzed in duplicate using 0.2 μmol/L specific
primers (Table 1) and 1× LightCycler 480 SYBR green I
Master (Roche Applied Science, Germany) in a total vol-
ume of 10 μl. GAPDH was used as an endogenous con-
trol. PCRs were carried out in a Light Cycle 480 (Roche
Applied Science, Germany) using a thermal profile of
10 min at 95 °C followed by 50 cycles of 15 s at 95 °C,
30 s at 60 °C, a melting curve of 15 s at 95 °C, 60 s at
1 min, heating to 95 °C, and cooling for 30 s at 4 °C.
The results were analyzed using LightCycler 480 soft-
ware (version 1.5, Roche Applied Science, Germany).
Relative levels of mRNA were analyzed using the ΔΔCt
method.
Western blotting
Frozen hippocampus samples were cut into small pieces
and homogenized in ice-cold extraction buffer [37].
Homogenates were centrifuged at 12,000×g for 15 min
at 4 °C. With the homogenates restored by agitation, the
centrifugation was repeated and the final supernatants
obtained. In contrast to frozen hippocampus tissues, BV-
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2 cells and HT-22 cells were washed twice with PBS (pH
7.4) and centrifuged at 1000 rpm for 5 min. Cell pellets
were lysed in an ice-cold extraction buffer [37]. Cell ly-
sates were centrifuged at 12,000×g for 15 min at 4 °C.
The supernatant was collected and used for further pro-
tein concentration analyses. Nuclear extracts only for
NF-κB p65 analysis were obtained with a nuclear isola-
tion kit (Beyotime Institute of Biotechnology, Shanghai,
China). Protein concentrations were determined using a
Pierce BCA Protein Assay Kit (Beyotime Institute of Bio-
technology, Shanghai, China). Equal amounts of protein
were separated by 10% SDS-polyacrylamide gel electro-
phoresis and transferred onto nitrocellulose membranes.
Membranes were blocked via 5% skim milk powder in
Tris-buffered saline including 0.05% (v/v) Tween 20
(TBST) for 2 h at 25 °C and then incubated overnight
with the primary antibodies to NF-κB p65 (1:1000), SYN
(1:1000), PSD-95 (1:2000) (Cell Signaling Technology,
Inc., Danvers, MA, USA), and β-actin (1:1000; ZSGB-
BIO, Beijing, China). Membranes were washed thrice
with TBST over 15 min and incubated with secondary
antibodies (ZSGB-BIO, Beijing, China) in 5% skim
milk powder in TBST. The membranes were exposed
to BCIP/NBT alkaline phosphatase color developing
reagent (Beyotime Institute of Biotechnology, Shang-
hai, China) for 15 min. Bands corresponding to the
proteins of interest were scanned and band density
analyzed using the Quantity One automatic imaging
analysis system (Bio-Rad). All quantitative analyses
were normalized to β-actin, as per our previous stud-
ies [38, 39].
Golgi staining
Golgi staining was used to assess neuronal morphom-
etry, as is widely used in the research of neurodegenera-
tive disorders [39]. The mice brains (n = 3 per group)
were stained using a Golgi-staining kit following the
manufacturer’s protocol (Genmed Scientifics Inc.,
Arlington, MA, USA). Golgi-stained brains were sec-
tioned using a vibratome (LEICA VT 1000S) at room
temperature (100 μm). The sections were visualized under
an upright microscope by two independent researchers
blinded to the experiment design (Olympus BX43F micro-
scope, Tokyo, Japan). For spine analysis, the dendrites in
20–30-μm lengths of the three tertiary segments were
used to measure dendritic spine density. Three neuronal
cells per brain slice and three brain slices per animal were
chosen for spine quantitative analysis [40].
Cell culture and treatment
BV-2 cells and HT-22 cells were obtained from Jiangsu
Key Laboratory of New Drug Research and Clinical
Pharmacy, Xuzhou Medical University (Xuzhou, China).
Dulbecco’s modified Eagle’s medium (DMEM) and fetal
bovine serum (FBS) were purchased from Gibco (Grand
Island, NY, USA). The cells were grown in DMEM con-
taining 10% FBS, 100 U/mL penicillin, and 100 U/mL
streptomycin at 37 °C in a humidified atmosphere of
95% air and 5% CO2. Galantamine was from ApexBIO
(Cat NO: A3423). LPS (Escherichia coli, serotype 0127:
B8) was obtained from Sigma (St. Louis, MO). For ex-
periments indicated below, BV-2 cells were exposed to
LPS (1 μg/ml) or pretreated with galantamine (10 μM)
Table 1 Primer sequences for RT-PCR analysis
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for 24 h before LPS exposure. Hippocampal neuronal
cells (HT-22 cells) were exposed to LPS (1 μg/ml), the
supernatant of LPS-stimulated microglia (Mi-sup) or
pretreated with galantamine (10 μM) for 24 h prior to
Mi-sup exposure.
Cell viability assay
BV-2 cells and HT-22 cells were seeded and grown for
24 h in 96-well plates at a density of 5 × 103 cells/well. The
cells were exposed to LPS (1 μg/mL) or Mi-sup for 24 h.
After the well was exposed to 3-(4,5-dimethylthiazol-2-yl)-
2,5-dipheyltetrazolium bromide (MTT) (0.5 mg/mL) for
4 h, the MTT was gently removed by aspiration. The for-
mazan crystals were dissolved in dimethyl sulfoxide and
the absorbance read at 550 nm by a microplate reader.
Cell viability was expressed as a percentage of untreated
control cells.
Immunofluorescent staining
BV-2 cells were seeded on glass cover slips in a 24-well
plate at 1 × 104 cells/well and cultured with the Mi-sup at
37 °C for 24 h. After treatment, BV-2 cells were washed
three times with PBS, immediately fixed in 4% paraformal-
dehyde for 30 min and permeabilized with 0.5% Triton X-
100 for 15 min. The cells were incubated with primary
antibodies against NF-κB p65 (1:50 dilution) overnight at
4 °C. Cells were then washed three times with PBS and in-
cubated with FITC-conjugated goat anti-rabbit secondary
antibody (1:200 dilution) for 1 h at room temperature.
Cells were washed three times in PBS and stained with
DAPI (10 μg/mL) for nuclear identification. The image
was visualized and captured by a microscope (Olympus
X51W, Olympus Microsystems).
Statistical analysis
The statistical comparisons were analyzed by two-way
repeated measures ANOVA, two way ANOVA, or one-
way ANOVA followed by LSD post hoc comparisons for
data with equal variances, or by Dunnett’s T3 for data
with unequal variances. All analyses were performed
using SPSS16.0. P values of less than 0.05 were regarded
as statistically significant. All values are expressed as
mean ± SEM.
Results
Galantamine improves cognition in LPS-exposed mice
Spatial learning and memory along with memory acqui-
sition of the passive avoidance response were measured
in response to LPS exposure and galantamine treatment
by the MWM test and the step-through test respectively.
Two-way repeated measures ANOVA showed that the
escape latency was significantly different among groups
(F3,36 = 13.659, P < 0.001), and there was a significant ef-
fect of test time (F4,36 = 20.543, P < 0.001). There was no
interaction effect of groups and test time (F12,36 = 1.307,
P = 0.221). During training trials from days 2–4, LPS-
exposed mice showed an increase in escape latency com-
pared to the control mice (Fig. 1a, all P < 0.01). However,
the escape latency during training days 2–4 was signifi-
cantly decreased in the LPS + galantamine group com-
pared to the LPS group (all P < 0.05). There was no
significant difference in escape latency between the gal-
antamine control and control groups (P > 0.05). In the
probe trial on day 5, mice in the LPS group showed
increased escape latency (P < 0.01, Fig. 1a) and de-
creased frequency of crossing the former platform lo-
cation (P < 0.01, Fig. 1b) compared with mice form
the control group, indicating that spatial memory re-
lated to the visual cues was decreased in LPS-treated
mice. The LPS + galantamine group showed a signifi-
cant decrease in the escape latency (P < 0.05, Fig. 1a)
and increase in frequency of crossing the former platform
location compared with the LPS group (P < 0.05, Fig. 1b).
The galantamine control group performed similarly to the
control group (P > 0.05; Fig. 1), indicating that galanta-
mine per se did not influence the spatial learning and
memory of mice in the control group.
In the step-through test, two-way ANOVA-indicated
LPS (F1,36 = 21.432, P < 0.001) and galantamine (F1,36 = 9.
983, P = 0.003) both showed effects on the step-through
latency, and there was an interaction effect between LPS
and galantamine (F1,36 = 11.122, P = 0.002). LPS injection
decreased the step-through latency compared to the
control group (P < 0.01), while the step-through latency
of the LPS + galantamine treatment group was increased
compared to the LPS group (P < 0.01, Fig. 1c). In
addition, two-way ANOVA indicated that the number of
mistakes was significantly affected by LPS (F1,36 = 17.894,
P < 0.001), but not galantamine (F1,36 = 1.988, P = 0.167),
and there was an interaction effect between LPS and gal-
antamine (F1,36 = 8.576, P = 0.006). The number of mis-
takes made by the LPS group significantly increased
compared to the control group (P < 0.01, Fig. 1d), while the
number of errors in the LPS + galantamine group was sig-
nificantly decreased compared to the LPS group (P < 0.01).
There were no statistical differences between the control
and galantamine control groups in step-through latency to
initial entry or in the number of mistakes (P > 0.05).
Galantamine prevents the upregulation of CD11b
and GFAP mRNA levels in the hippocampus of the
LPS-exposed mice
Activation of neuroglia is implicated in the pathogenesis of
memory decline in neuroinflammatory and neurodegenera-
tive diseases [12, 41, 42]. We examined the mRNA level of
the microglia and astrocyte markers, CD11b and GFAP, in
the hippocampus in response to LPS and galantamine.
Two-way ANOVA showed that LPS and galantamine
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affected CD11b mRNA expression (LPS, F1,16 = 158.084, P
< 0.001; galantamine, F1,16 = 87.914, P = 0.003) and GFAP
mRNA expression (LPS, F1,16 = 39.174, P < 0.001; galanta-
mine, F1,16 = 14.931, P = 0.001). There were also significant
interaction effects between LPS and galantamine on CD11b
mRNA (F1,16 = 125.232, P < 0.001) and GFAP mRNA (F1,16
= 19.342, P < 0.001). LPS significantly increased CD11b
mRNA expression (P < 0.001, Fig. 2a) and GFAP mRNA ex-
pression (P < 0.001, Fig. 2b) in the hippocampus compared
to the control group. Galantamine treatment (LPS + galan-
tamine group) significantly prevented the elevation of
CD11b and GFAP mRNA induced by LPS (both P < 0.001;
Fig. 2). These results suggest that galantamine prevents
microglial and astrocyte activation in the hippocampus of
mice following LPS exposure.
Galantamine prevents the upregulation of NF-κB p65, and
IL-1β, IL-6, and TNF-α mRNA levels in the hippocampus of
LPS-exposed mice
To further determine whether changes in neuroglia
could be associated with neuroinflammation, we
Fig. 1 Galantamine improved the cognition in LPS-exposed mice. a Escape latency during the training and the probe sessions in MWM test. b Times of
crossing the former platform location during the probe trial in MWM test. Step-through latency (c) and error number (d) in the step-through test. Data
are reported as mean ± SEM (n = 10). *P < 0.05, **P < 0.01, as compared with the control group; #P< 0.05, ##P< 0.01, as compared with the LPS group
Fig. 2 Galantamine prevented the activation of neuroglia cells in the hippocampus of the LPS-exposed mice. The mRNA levels of CD11b (a) and
GFAP (b) in the hippocampus of mice were examined by reverse transcriptase-PCR (RT-PCR). The level of each mRNA was normalized to the
mRNA level of β-actin as an endogenous control. Data are reported as mean ± SEM (n = 5). **P < 0.01, ***P < 0.001, as compared with the control
group; ##P < 0.01, ###P < 0.001, as compared with the LPS group
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measured the protein levels of NF-κB p65, transcription
factors in inflammatory signaling. Two-way ANOVA
showed that the levels of NF-κB p65 were affected by
LPS (F1,16 = 49.842, P < 0.001), galantamine (F1,16 = 12.
964, P = 0.002) and the interaction between LPS and gal-
antamine (F1,16 = 38.906, P < 0.001). LPS exposure sig-
nificantly increased NF-κB p65 in the hippocampus
compared to the control group (P < 0.001; Fig. 3a).
Galantamine treatment significantly prevented the LPS-
induced NF-κB p65 elevation in mice (P < 0.001; Fig. 3a).
There were no significant differences in the levels of NF-
κB p65 between the control and galantamine control
groups (P > 0.05; Fig. 3a). These results suggest that gal-
antamine prevents LPS-induced activation of NF-κB
p65, a transcription factor that plays crucial roles in
neuroinflammation.
Next, we examined if galantamine could decrease the
mRNA expression of the proinflammatory cytokines, IL-
1β, IL-6, and TNF-α, which are transcribed by NF-κB.
Two-way ANOVAs indicated that the mRNA expression
of pro-inflammatory factors were affected by LPS and
galantamine, including IL-1β (LPS, F1,16 = 76.534, P < 0.
001; galantamine, F1,16 = 43.762, P < 0.001), IL-6 (LPS,
F1,16 = 73.814, P < 0.001; galantamine, F1,16 = 11.453, P =
0.004), and TNF-α (LPS, F1,16 = 27.326, P < 0.001; galan-
tamine, F1,16 = 4.205, P = 0.057). LPS and galantamine
had significant interaction effects on the mRNA expres-
sion of IL-1β (F1,16 = 48.854, P < 0.001), IL-6 (F1,16 = 19.
740, P < 0.001), and TNF-α (F1,16 = 5.427, P = 0.033). LPS
exposure significantly increased the mRNA expression
of IL-1β (P < 0.001; Fig. 3b), IL-6 (P < 0.001; Fig. 3c), and
TNF-α (P < 0.001; Fig. 3d) in the hippocampus compared
to the control group. Galantamine treatment signifi-
cantly prevented the LPS-induced upregulation of these
pro-inflammatory cytokine transcripts (IL-1β: P < 0.001,
IL-6: P < 0.01, TNF-α: P < 0.01; Fig. 3). There were no
significant differences in IL-1β, IL-6, and TNF-α mRNA
expression between the control and galantamine control
groups (all P > 0.05; Fig. 3).
Galantamine prevents the reduction of synapse-
associated proteins and neurodegeneration in the
hippocampus of LPS-exposed mice
There is growing evidence that synaptic dysfunction and
degeneration contribute to the deterioration of memory
performance [43, 44]. In the two-way ANOVA, we found
that LPS and galantamine significantly affected synaptic
proteins including SYN (LPS, F = 21.010, P < 0.001; gal-
antamine, F1,16 = 4.713, P = 0.045) and PSD-95 (LPS,
F1,16 = 78.366, P < 0.001; galantamine, F1,16 = 16.830, P =
0.001). There were also interaction effects between LPS
and galantamine on SYN (F1,16 = 13.690, P = 0.002) and
PSD-95 (F1,16 = 49.130, P < 0.001). Western blot analyses
showed a reduction of the pre-synaptic protein SYN
(P < 0.001, Fig. 4a) and post-synaptic protein PSD-95
(P < 0.001, Fig. 4b) in the hippocampus of mice treated
with LPS. Treatment with galantamine significantly at-
tenuated the decline of both SYN and PSD-95 proteins
in the hippocampus of LPS mice compared to LPS-
treated mice (P < 0.001, Fig. 4a b). In serial coronal sec-
tions of the hippocampus, neurons in the LPS mice had
less dendritic branching, reduced branch length, and de-
creased complexity of dendritic trees in the hippocampal
CA1 subfield compared to the other groups, which was
reversed by galantamine treatment (Fig. 4c). In addition,
dendritic spine density was also significantly decreased in
LPS mice, which was restored by galantamine (P < 0.001,
Fig. 4d).
The activation of microglia and astrocytes has been
found to be involved in synaptic plasticity in mice [45].
Thus, we examined the correlations between the synaptic
proteins and the levels of CD11b and GFAP mRNA in the
hippocampus. Pearson correlation analysis showed that
there was a remarkable negative correlation between
CD11b and GFAP mRNA levels with SYN expression in
the hippocampus (CD11b: r = − 0.838, P < 0.001, Fig. 5a;
GFAP: r = − 0.713, P < 0.001, Fig. 5b). Furthermore, there
were significant negative correlations between CD11b and
GFAP mRNA levels with PSD-95 expression in the hippo-
campus (CD11b: r = − 0.909, P < 0.001 Fig. 5c; GFAP: r = −
0.836, P < 0.001, Fig. 5d).
Mi-sup rather than LPS decreases HT-22 cell viability and
increases the levels of NF-κB p65 in HT-22 cells, and LPS
increases the levels of NF-κB p65 in BV-2 cells
The cytotoxicity of LPS on cell viability of HT-22 cells (a
hippocampal neuronal cell line) and BV-2 cells (a
microglia-derived cell line) were determined by the MTT
assay 12, 24, and 48 h after LPS or Mi-sup exposure.
Two-way repeated measures ANOVA indicated that LPS
and time did not significantly influence HT-22 cell viabil-
ity (F1,4 = 0.007, P = 0.938; F2,4 = 0.166, P = 0.717, Fig. 6a).
There was no interaction effect between LPS and time
(F2,4 = 0.166, P = 0.717). However, the HT-22 cell viability
was significantly affected by Mi-sup exposure and time and
there was an interaction between two factors (F1,4 = 257.
606, P < 0.001; F2,4 = 9.487, P = 0.008; F2,4 = 9.487, P = 0.
008). After 24 and 48 h of Mi-sup exposure, HT-22 cell via-
bility was significantly decreased compared with the control
group (both P < 0.001, Fig. 6b). Therefore, LPS did
not directly decrease HT-22 viability, but the super-
natant of LPS-stimulated BV-2 microglia decreased
HT-22 cell viability.
Next, the pro-inflammatory signaling molecule, NF-κB
p65, was examined by western blot in BV-2 cells and HT-
22 cells in response to LPS or Mi-sup. LPS significantly in-
creased the levels of NF-κB p65 in BV-2 cells (P < 0.001,
Fig. 6c), but not in HT-22 cells (P > 0.05, Fig. 6d)
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compared to the control group. However, in HT-22 cells,
the levels of NF-κB p65 were significantly increased by
Mi-sup (P < 0.001, Fig. 6e). We further confirmed that im-
munofluorescence of NF-κB p65 was increased in HT-
22 cells in response to Mi-sup exposure (P < 0.001, Fig.
6f ). These observations suggest that LPS activates NF-
κB signaling on HT-22 neurons indirectly via activating
BV-2 microglia first.
Galantamine prevents the increase of NF-κB p65 in BV-2
cells and HT-22 cells
To further explore the anti-neuroinflammatory mechan-
ism of galantamine, we examined whether galantamine
can prevent the increase of NF-κB p65 in LPS-exposed
BV-2 cells and Mi-sup-exposed HT-22 cells. Here we
found that galantamine treatment (10 μM) resulted in a
decrease of NF-κB p65 in BV-2 cells compared to the
Fig. 3 Galantamine attenuated neuroinflammation in the hippocampus of LPS-exposed mice. The protein level of NF-κB p65 was examined by
western blot (a). The mRNA levels of IL-1β (b), IL-6 (c), and TNF-α (d) in the hippocampus of mice were examined by reverse transcriptase-PCR
(RT-PCR). The level of each mRNA was normalized to the mRNA level of β-actin as an endogenous control. Data are reported as mean ± SEM
(n = 5). **P < 0.01, ***P < 0.001, as compared with the control group; ##P < 0.01, ###P < 0.001, as compared with the LPS group
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LPS group (P < 0.01, Fig. 7a) and in HT-22 cells versus
the Mi-sup group (P < 0.05, Fig. 7b). Furthermore, Mi-
sup increased pro-inflammatory cytokines IL-1β and IL-
6 mRNA, but not TNF-α mRNA expression, in HT-22
cells, while galantamine inhibited the inflammation in-
duced by Mi-sup (Fig. 7c–e).
Discussion
This study showed that galantamine prevented LPS-
induced cognitive deficits, including deficits in spatial
learning and memory as well as memory acquisition of
the passive avoidance response in mice. Of particular
significance were the findings that galantamine inhibited
the gliosis, activation of microglia and astrocyte, the ex-
pression of NF-κB p65 and pro-inflammatory cytokines
in the hippocampus of LPS-exposed mice. Consequently,
galantamine ameliorated LPS-induced reductions in hip-
pocampal synaptic proteins, and dendritic branching and
spine density. Further, LPS induced neuroinflammation
by directly activating the microglia, whereas galantamine
Fig. 4 Galantamine prevented the reduction of synapse-associated proteins and neurodegeneration in the hippocampus of LPS-exposed mice. The protein
levels of SYN (a) and PSD-95 (b) were examined by western blot. Data are reported as mean± SEM (n= 5). Golgi silver-stained neurons in the hippocampal
CA1 subfield (c). Representative images are shown (n = 3). Bar = 100 μm. d Representative dendritic spine and dendritic spine density at the CA1 hippocampal
region (n = 3). Bar = 10 μm. **P< 0.01, ***P< 0.001, as compared with the control group; ##P< 0.01, ###P< 0.001, as compared with the LPS group
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reduced the inflammatory response not only in
microglia, but also in hippocampal neurons. Such central
anti-neuroinflammatory effects of galantamine may con-
tribute to the observed improvement in cognition.
The MWM test and step-through test were used as ro-
bust and reliable tests that reflect hippocampal-
dependent learning and memory [46–49]. We observed
that LPS-induced cognitive impairments were prevented
by galantamine treatment (4 mg/kg ip). Consistently in
clinical studies, long-term galantamine treatment im-
proves cognition deficits in patients with Alzheimer’s
disease [50]. Some research has shown that neuroinflam-
matory processes are related to the pathogenesis of
Alzheimer’s disease. For example, LPS levels are in-
creased in brain samples from late-onset Alzheimer’s
disease patients [10], suggesting that LPS may be in-
volved in the cognitive impairment in Alzheimer’s dis-
ease. Overall, these suggest that galantamine may have
potential to protect against LPS-induced cognition im-
pairments in neurodegenerative diseases.
In the present study, LPS ICV injection increased the
expression of the microglia marker, CD11b, in the
mouse hippocampus. CD11b is one of the most import-
ant surface markers of microglia. According to reports,
increased expression of CD11b corresponds to the sever-
ity of microglial activation in various neuroinflammatory
diseases [51]. Furthermore, microglial activation and
secretion of pro-inflammatory cytokines can induce pro-
inflammatory A1 astrocytes, which are detrimental to
neuronal survival, outgrowth, synaptogenesis, and
phagocytosis [11]. In this study, in the hippocampus,
LPS ICV injection also increased mRNA expression of
GFAP (a marker of astrocyte activation) in mice, which
may be attributed to activated microglia. The GFAP pro-
tein in cultured astrocytes increases approximately
threefold in A1 astrocytes compared to control [11].
Therefore, the LPS injection may activate microglia and
thereafter induce A1 astrocyte accumulation in the
hippocampus.
Importantly, in this study, galantamine treatment pre-
vented activation of microglia and astrocytes and im-
proved neuroinflammation by inhibition of inflammatory
signaling molecule (NF-κB p65) and cytokines (TNF-α,
IL-1β and IL-6) in the hippocampus of LPS-exposed
mice. Activation and translocation of NF-κB into the nu-
cleus mediates the transcription of pro-inflammatory
cytokine genes, including TNF-α, IL-1β, and IL-6 [52].
The “cholinergic anti-inflammatory pathway” is medi-
ated by ACh binding to α7 nicotinic receptors to sup-
press the activation of NF-κB and inhibit the production
of pro-inflammatory cytokines [53]. ACh dose-
dependently decreases the release of TNF-α, IL-1β, and
IL-6 from LPS-activated primary human macrophages
[54]. Galantamine is an AChE inhibitor, which inhibits
a b
c d
Fig. 5 Correlations between synapse-associated proteins and glia markers. There were negative correlations between synapse-associated proteins
(SYN and PSD-95) and glia markers (CD11b and GFAP) (a–d)
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the AChE from dissociating ACh, thereafter increasing
both the level and duration of action of the neurotrans-
mitter ACh. Therefore, the anti-inflammatory action of
galantamine may be mediated via microglia and astro-
cyte inhibition of the NF-κB signaling pathway. The
protocol used in this study involved pretreatment of the
mice with galantamine before the administration of LPS;
while this is not consistent with treatment approaches in
clinical settings in AD, for post-operative cognitive de-
cline, galantamine pre-treatment may be helpful to pre-
vent the postoperative neuroinflammation and cognitive
dysfunction [55].
The synapse-associated proteins, especially presynaptic
SYN and postsynaptic PSD-95, promote synaptic
Fig. 6 Mi-sup but not LPS decreased the viability and activated NF-κB p65 of HT-22 cells. MTT assays were performed to detect the cell viability in
HT-22 cells treated with LPS (a) or Mi-sup (b) for 12, 24, or 48 h. Results are expressed relative to control and are presented as means ± SEM of three
independent experiments (each performed in triplicate). The levels of NF-κB p65 in LPS-exposed BV-2 cells (c) and LPS-exposed HT-22 cells (d) were
determined by western blot. HT-22 cells were exposed to Mi-sup for 24 h, and then the activation of NF-κB p65 was determined by western blot (e)
and immunofluorescence staining (f). Data are presented as means ± SEM (n = 5). *P < 0.05, **P < 0.01,***P < 0.001 vs control group
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plasticity [56–58]. Deficits in SYN and PSD-95 correlate
with cognition decline in neurodegenerative disorders,
such as Alzheimer’s disease and aging [18, 19]. For ex-
ample, SYN levels have been found to be decreased in
the brains of oldest-aged individuals with dementia [18].
Moreover, PSD-95 levels were decreased in the brains of
patients with Alzheimer’s disease cases compared with
controls [19]. Aberrant dendrites and spines in the
hippocampus are related to neurodegenerative disorders,
such as Alzheimer’s disease [59]. In this study, the levels
of presynaptic SYN and postsynaptic PSD-95 decreased
in the hippocampus of LPS-exposed mice. Golgi staining
showed that LPS decreased dendritic branching and
dendritic spine density in the hippocampal CA1 subfield.
Consistently, abnormal hippocampal neuronal plasticity
has been found following neuroinflammation induced by
ICV administration of LPS in rats [60]. This LPS-
induced decrease in synaptic protein levels may contrib-
ute to impairment of synaptic plasticity and the learning
and memory decline observed in behavioral tests,
suggesting impairments of synaptic plasticity may be
responsible for LPS-induced cognitive deficits. Interest-
ingly, in our study, chronic treatment with galantamine
prevented the LPS-induced reduction of SYN and
PSD-95, and increased dendritic spine density, in the
hippocampus. Furthermore, we also found negative
correlations between CD11b or GFAP mRNA levels
and synaptic proteins in the hippocampus, which sug-
gests that the excessive activation of microglia and
astrocyte may contribute to decreasing the synaptic
proteins in the hippocampus. Therefore, galantamine
may contribute to improved cognition in this neu-
roinflammatory animal model by prevention of neuro-
inflammation and increase of synaptic proteins in the
hippocampus.
At the cellular level, this study found that microglia
responded directly to LPS, while HT-22 cells responded to
Mi-sup rather than LPS. In MTT assays, cell viability of
HT-22 cells was not affected by LPS exposure. Previously,
LPS did not increase Ca2+ and neither promoted neuronal
apoptosis in young cultured primary hippocampal
neurons expressing low levels of TLR4 [61]. Therefore,
LPS may not directly impair neurons but induce
neuroinflammation by firstly activating microglia. In our
study, we found that cell viability of HT-22 cells was sig-
nificantly decreased by exposure of Mi-sup, which pro-
duces proinflammatory cytokines and induces neural
apoptosis [62]. Furthermore, in western blotting, we found
Fig. 7 Galantamine prevented the increase of NF-κB p65 in LPS-exposed BV-2 cells, and the increase of NF-κB p65, IL-1β, and IL-6 in Mi-sup-exposed
HT-22 cells. The protein level of NF-κB p65 was examined by western blot (a b), and the mRNA expression of IL-1β, IL-6, and TNF-α were examined
by real-time PCR (c-e). Data are reported as mean ± SEM (n = 5). *P < 0.05, **P < 0.01, as compared with the control group; #P < 0.05, ##P < 0.01, as
compared with the LPS group or Mi-sup group
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that LPS directly increased NF-κB p65 level in BV-2 cells
but not HT-22 cells, while the levels of NF-κB p65 in HT-
22 cells were significantly increased by Mi-sup. Overall,
the above results suggest that activated microglia are es-
sential in LPS-induced neuroinflammation and mediate
neuronal impairment. In the present study, galantamine
prevented the increase of NF-κB p65 in BV-2 cells and
HT-22 cells induced by Mi-sup. It suggests galantamine
acted on the dual targets in BV-2 cells and HT-22 cells for
prevention of LPS-induced neuroinflammation and neur-
onal impairment.
Conclusion
This study indicates that galantamine induces cognitive im-
provement and anti-neuroinflammatory effects in central
LPS-exposed mice. Galantamine prevented LPS-induced
cognitive deficits, including spatial learning and memory as
well as memory acquisition of the passive avoidance
response. Galantamine also inhibited the gliosis, pro-
inflammatory signaling molecules (NF-κB p65), and
cytokines (IL6, IL-1β and TNF-α) and increased the
synapse-associated proteins in the hippocampus of LPS-
exposed mice. Furthermore, the vitro evidence showed that
galantamine’s therapeutic mechanisms are not only in re-
ducing the inflammatory response in microglia, but also in
hippocampal neurons evidenced by galantamine’s ability to
prevent the upregulation of NF-κB p65 in both BV-2
cells and HT-22 cells. These behavioral and neuro-
chemical improvements in in vivo and in vitro studies
suggest that galantamine may be a promising treatment
to improve endotoxin-induced cognitive decline and
neuroinflammation.
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